SCHEMBL1016303

SCHEMBL1016303

O=C(COCC(=O)Nc1ccc(Cl)cc1C(=O)O)Nc1cccc(OCc2ccco2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 5/20 0.55
POLB P06746 2/20 0.51
G6PD P11413 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.46
TP53 P04637 2/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 4/20 0.45
HPGD P15428 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 3/20 0.43
GAA P10253 1/20 0.43
TRPM4 Q8TD43 2/20 0.43
DVL1 O14640 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1013870 0.91 ALDH1A1 (0.45) SERPINE1POLBSMN1; SMN2TP53ALDH1A1
SCHEMBL1013840 0.87 SERPINE1 (0.55) SERPINE1POLBG6PDSMN1; SMN2TP53
SCHEMBL1014818 0.82 SERPINE1 (0.56) SERPINE1POLBG6PDSMN1; SMN2ALDH1A1
SCHEMBL1015206 0.78 KDM4E (0.47) SERPINE1POLBSMN1; SMN2TP53ALDH1A1
SCHEMBL419303 0.78 SERPINE1 (0.74) SERPINE1POLBG6PDSMN1; SMN2TP53
SCHEMBL29492572 0.76 SERPINE1 (0.77) SERPINE1POLBG6PDALDH1A1MAPT
SCHEMBL1016107 0.76 SERPINE1 (0.77) SERPINE1POLBG6PDALDH1A1MAPT
SCHEMBL1797569 0.76 SERPINE1 (0.56) SERPINE1POLBG6PDSMN1; SMN2TP53
SCHEMBL1015100 0.76 SERPINE1 (0.55) SERPINE1POLBG6PDMAPTKDM4E
SCHEMBL22468222 0.76 SERPINE1 (0.75) SERPINE1POLBG6PDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SERPINE1 1/4885POLB 2992/4885G6PD 493/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2824/4885G6PD 387/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885POLB 2556/4885G6PD 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.